Figures computed from official regulatory filings — .
Analysttarget 9.2 USD (+151%) · consensus 4.6/5 · 5 buy · 0 hold · 0 sell
Ownershipinsiders 13.76% · institutions 76.44% · short 14.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Prelude Therapeutics Inc only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
41 buys67 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| BAKER BROS. ADVISORS LPtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) |
| Bonita David Ptrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| FRIEDMAN PAUL Atrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Babler Martin | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BAKER BROS. ADVISORS LPtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sandor Victor | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Dorton Katina | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Morris Charles Q | AwardD (derivative) | $2.1M | Unusual size | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| RA CAPITAL MANAGEMENT, LLCtrack record | Other | n/a (No price was disclosed in the filing) | SEC |
| Bonita David Ptrack record | Buy | $7.5M | conv 38Cluster | SEC |
| ORBIMED ADVISORS LLCtrack record | Buy | $5M | conv 45Cluster | SEC |
| Bonita David Ptrack record | Buy | $5M | conv 38Cluster | SEC |
| ORBIMED ADVISORS LLCtrack record | Buy | $7.5M | conv 46Cluster | SEC |
| BAKER BROS. ADVISORS LPtrack record | BuyD (derivative) | $9.5M | ClusterFirst in 12mo | SEC |
| BAKER BROS. ADVISORS LPtrack record | BuyD (derivative) | $508.8K | ClusterFirst in 12mo | SEC |
| Combs Andrewtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Scherle Peggy | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Vaddi Krishnatrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lim Bryant David | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Sandor Victor | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Dorton Katina | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Huang Jane | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Huang Jane | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Huang Jane | Other | $4.9K | SEC |